Dyne Therapeutics Inc, a muscular disease therapies developer, raised $233 million by offering 12.3 million Ads at $19, above the proposed range of $16 to $18.
The company designed its proprietary FORCE platform to overcome current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Their initial focus programs on potential pipeline expansion opportunities in additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle disease.
The Waltham, Massachusetts-based company was founded in 2017. It plans to list on the Nasdaq Global Market under the symbol “DYN.” J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriters of the IPO.
The company engages Wilmer Cutler Pickering Hale and Dorr LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
#ipo #nasdaq #deloitte #muscledisease #healthcare #therapydeveloper
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
